Genetic diversity and evolution of hepatitis C virus - 15 years on

Journal of General Virology

Volumn 85, Issue 11, 2004, Pages 3173-3188

  Simmonds, Peter ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BILN 2065; ENZYME INHIBITOR; EPITOPE; INTERFERON; PROTEIN KINASE; PROTEINASE; PROTEINASE INHIBITOR; RIBAVIRIN; RNA POLYMERASE; VIRUS ENZYME;

ANTIGEN RECOGNITION; ANTIVIRAL ACTIVITY; B LYMPHOCYTE; BIOLOGICAL TRAIT; DISEASE COURSE; DRUG SENSITIVITY; DRUG TARGETING; ECOLOGICAL NICHE; FLAVIVIRUS; GENETIC CONSERVATION; GENETIC VARIABILITY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RESPONSE; LIVER DISEASE; MOLECULAR EVOLUTION; NONHUMAN; NUCLEOTIDE SEQUENCE; PERSISTENT VIRUS INFECTION; PHYLOGENETIC TREE; POPULATION SIZE; PRIORITY JOURNAL; REVIEW; SEQUENCE ANALYSIS; SYSTEMATIC REVIEW; T LYMPHOCYTE; VIRUS CELL INTERACTION; VIRUS CLASSIFICATION; VIRUS INFECTIVITY; VIRUS MUTATION; VIRUS PATHOGENESIS; VIRUS RECOMBINATION; VIRUS TRANSMISSION; VIRUS VIRULENCE;

DISEASE TRANSMISSION, HORIZONTAL; EVOLUTION; GENOME, VIRAL; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; LIVER; RNA, VIRAL; VARIATION (GENETICS); VIRAL ENVELOPE PROTEINS; VIRAL NONSTRUCTURAL PROTEINS;

FLAVIVIRIDAE; HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 7444256169     PISSN: 00221317     EISSN: None     Source Type: Journal    
DOI: 10.1099/vir.0.80401-0     Document Type: Review

References (144)

1. Adinolfi, L. E., Gambardella, M., Andreana, A., Tripodi, M.-F., Utili, R. & Ruggiero, G. (2001). Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 33, 1358-1364.
2. Bartenschlager, R., Kaul, A. & Sparacio, S. (2003). Replication of the hepatitis C virus in cell culture. Antiviral Res 60, 91-102.
3. Blight, K. J., Kolykhalov, A. A. & Rice, C. M. (2000). Efficient initiation of HCV RNA replication in cell culture. Science 290, 1972-1974.
4. Blight, K. J., McKeating, J. A., Marcotrigiano, J. & Rice, C. M. (2003). Efficient replication of hepatitis C virus genotype 1a RNAs in cell culture. J Virol 77, 3181-3190.
5. Booth, J. C., Kumar, U., Webster, D., Monjardino, J. & Thomas, H. C. (1998). Comparison of the rate of sequence variation in the hypervariable region of E2/NS1 region of hepatitis C virus in normal and hypogammaglobulinemic patients. Hepatology 27, 223-227.
6. Bukh, J., Purcell, R. H. & Miller, R. H. (1993). At least 12 genotypes of hepatitis C virus predicted by sequence analysis of the putative E1 gene of isolates collected worldwide. Proc Natl Acad Sci U S A 90, 8234-8238.
7. Bukh, J., Pietschmann, T., Lohmann, V. & 7 other authors (2002). Mutations that permit efficient replication of hepatitis C virus RNA in Huh-7 cells prevent productive replication in chimpanzees. Proc Natl Acad Sci U S A 99, 14416-14421.
8. Candotti, D., Temple, J., Sarkodie, F. & Allain, J.-P. (2003). Frequent recovery and broad genotype 2 diversity characterize hepatitis C virus infection in Ghana, west Africa. J Virol 77 7914-7923.
9. Cantaloube, J.-F., Biagini, P., Attoui, H., Gallian, P., de Micco, P. & De Lamballerie, X. (2003). Evolution of hepatitis C virus in blood donors and their respective recipients. J Gen Virol 84, 441-446.
10. Chang, K.-M., Rehermann, B., McHutchison, J. G., Pasquinelli, C., Southwood, S., Sette, A. & Chisari, F. V. (1997 . Immunological significance of cytotoxic T lymphocyte epitope variants in patients chronically infected by the hepatitis C virus. J Clin Invest 100, 2376-2385.
11. Choo, Q. L., Kuo, G., Weiner, A. J., Overby, L. R., Bradley, D. W. & Houghton, M. (1989). Isolation of a cDNA derived from a blood-borne non-A, non-B hepatitis genome. Science 244, 359-362.
12. Clemens, M. J. & Elia, A. (1997). The double-stranded RNA-dependent protein kinase PKR: structure and function. J interferon Cytokine Res 17, 503-524.
13. Cochrane, A., Searle, B., Hardie, A. & 7 other authors (2002). A genetic analysis of hepatitis C virus transmission between injection drug users. J Infect Dis 186, 1212-1221.
14. Colina, R., Casane, D., Vasquez, S., García-Aguirre, L., Chunga, A., Romero, H., Khan, B. & Cristina, J. (2004). Evidence of intratypic recombination in natural populations of hepatitis C virus. J Gen Virol 85, 31-37.
15. Cooper, S., Erickson, A. L., Adams, E. J., Kansopon, J., Weiner, A. J., Chien, D. Y., Houghton, M., Parham, P. & Walker, C. M. (1999). Analysis of a successful immune response against hepatitis C virus. Immunity 10, 439-449.
16. De Francesco, R., Tomei, L., Altamura, S., Summa, V. & Migliaccio, G. (2003). Approaching a new era for hepatitis C virus therapy: inhibitors of the NS3-4A serine protease and the NS5B RNA-dependent RNA polymerase. Antiviral Res 58, 1-16.
17. de Lamballerie, X., Charrel, R. N., Attoul, H. & De Micco, P. (1997). Classification of hepatitis C virus variants in six major types based on analysis of the envelope 1 and nonstructural 5B genome regions and complete polyprotein sequences. J Gen Virol 78, 45-51.
18. Di Bisceglie, A. M. (1997). Hepatitis C and hepatocellular carcinoma. Hepatology 26, 34S-38S.
19. Domingo, E., Escarmis, C., Sevilla, N., Moya, A., Elena, S. F., Quer, J., Novella, I. S. & Holland, J. J. (1996). Basic concepts in RNA virus evolution. FASEB J 10, 859-864.
20. Dou, X-G., Talekar, G., Chang, J., Dal, X., Li, L., Bonafonte, M. T., Holloway, B., Fields, H. A. & Khudyakov, Y. E. (2002). Antigenic heterogeneity of the hepatitis C virus NS5A protein. J Clin Microbiol 40, 61-67.
21. Drake, J. W., Charlesworth, B., Charlesworth, D. & Crow, J. F. (1998). Rates of spontaneous mutation. Genetics 148, 1667-1686.
22. Enomoto, N., Sakuma, I., Asahina, Y., Kurosaki, M., Murakami, T., Yamamoto, C., Izumi, N., Marumo, F. & Sato, C. (1995 . Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b: sensitivity to interferon is conferred by amino acid substitutions in the NS5a region. J Clin Invest 96, 224-230.
23. Erickson, A. L., Kimura, Y., Igarashi, S. & 7 other authors (2001). The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes. Immunity 15, 883-895.
24. Farci, P., Alter, H. J., Govindarajan, S. & 8 other authors (1992). Lack of protective immunity against reinfection with hepatitis C virus. Science 258, 135-140.
25. Farci, P., Shimoda, A., Coiana, A. & 9 other authors (2000). The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science 288, 339-344.
26. Foy, E., Li, K., Wang, C., Sumpter, R., Jr, Ikeda, M., Lemon, S. M. & Gale, M., Jr (2003). Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science 300, 1145-1148.
27. Franchini, M., Rossetti, G., Tagliaferri, A. & 7 other authors (2001). The natural history of chronic hepatitis C in a cohort of HIV-negative Italian patients with hereditary bleeding disorders. Blood 98, 1836-1841.
28. Frank, C., Mohamed M. K, Strickland, G. T. & 8 other authors (2000). The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet 355, 887-891.
29. Frese, M., Pietschmann, T., Moradpour, D., Haller, O. & Bartenschlager, R. (2001). Interferon-α inhibits hepatitis C virus subgenomic RNA replication by an MxA-independent pathway. J Gen Virol 82, 723-733.
30. Fretz, C., Jeannel, D., Stuyver, L., Hervé, V., Lunel, F., Boudifa, A., Mathiot, C., de Thé G. & Fournel, J. J. (1995). HCV infection in a rural population of the Central African Republic (CAR): evidence for three additional subtypes of genotype 4. J Med Virol 47, 435-437.
31. Gale, M. J., Jr, Korth, M. J., Tang, N. M., Tan, S.-L., Hopkins, D. A., Dever, T. E., Polyak, S. J., Gretch, D. R. & Katze, M. G. (1997). Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. Virology 230, 217-227.
32. Gao, F., Yue, L., White, A. T. & 7 other authors (1992). Human infection by genetically diverse SIVSM-related HIV-2 in west Africa. Nature 358, 495-499.
33. Gao, F., Bailes, E., Robertson, D. L. & 9 other authors (1999). Origins of HIV-1 in the chimpanzee Pan troglodytes troglodytes. Nature 397, 436-441.
34. Gates, A. T., Sarisky, R. T. & Gu, B. (2004). Sequence requirements for the development of a chimeric HCV replicon system. Virus Res 100, 213-222.
35. Girardin, S. E., Sansonetti, P. J. & Philpott, D. J. (2002). Intracellular vs extracellular recognition of pathogens - common concepts in mammals and flies. Trends Microbiol 10, 193-199.
36. Gitlin, L. & Andino, R. (2003). Nucleic acid-based immune system: the antiviral potential of mammalian RNA silencing. J Virol 77, 7159-7165.
37. Gong, G., Waris, G., Tanveer, R. & Siddiqui, A. (2001). Human hepatitis C virus NS5A protein alters intracellular calcium levels, induces oxidative stress, and activates STAT-3 and NF-κB. Proc Natl Acad Sci U S A 98, 9599-9604.
38. González-Pérez, M. A., Norder, H., Bergström, Å., Lopéz, E., Visoná, K. A. & Magnius, L. 0. (1997). High prevalence of GB virus C strains genetically related to strains with Asian origin in Nicaraguan hemophiliacs. J Med Virol 52, 149-155.
39. Harvala, H., Kalimo, H., Dahllund, L., Santti, J., Hughes, P., Hyypiä, T. & Stanway, G. (2002). Mapping of tissue tropism determinants in coxsackievirus genomes. J Gen Virol 83, 1697-1706.
40. Heinz, F. X., Collett, M. S., Purcell, R. H., Gould, E. A., Howard, C. R., Houghton, M., Moorman, R. J. M., Rice, C. M. & Thiel, H.-J. (2000). Flaviviridae. In Seventh Report of the International Committee on Taxonomy of Viruses, pp. 859-878. Edited by M. H. V. van Regenmortel, C. M. Fauquet, D. H. L. Bishop, E. B. Carstens, M. K. Estes, S. M. Lemon, J. Maniloff, M. A. Mayo, D. J. McGeoch, C. R. Pringle & R. B. Wickner. San Diego, CA: Academic Press.
41. Holland-Staley, C. A., Kovari, L. C., Golenberg, E. M., Pobursky, K. J. & Mayers, D. L. (2002). Genetic diversity and response to IFN of the NS3 protease gene from clinical strains of the hepatitis C virus. Arch Virol 147, 1385-1406.
42. Hoofnagle, J. H. (2002). Course and outcome of hepatitis C. Hepatology 36, S21-S29.
43. Ikeda, M., Yi, M., Li, K. & Lemon, S. M. (2002). Selectable subgenomic and genome-length dicistronic RNAs derived from an infectious molecular clone of the HCV-N strain of hepatitis C virus replicate efficiently in cultured Huh7 cells. J Virol 76, 2997-3006.
44. Jarvis, L. M., Watson, H. G., McOmish, F., Peutherer, J. F., Ludlam, C. A. & Simmonds, P. (1994). Frequent reinfection and reactivation of hepatitis C virus genotypes in multitransfused hemophiliacs. J Infect Dis 170, 1018-1022.
45. Jeannel, D., Fretz, C., Traore, Y. & 9 other authors (1998). Evidence for high genetic diversity and long-term endemicity of hepatitis C virus genotypes 1 and 2 in West Africa. J Med Virol 55, 92-97.
46. Kalinina, O., Norder, H., Mukomolov, S. & Magnius, L. O. (2002). A natural intergenotypic recombinant of hepatitis C virus identified in St. Petersburg. J Virol 76, 4034-4043.
47. Kalinina, O., Norder, H. & Magnius, L. O. (2004). Full-length open reading frame of a recombinant hepatitis C virus strain from St Petersburg: proposed mechanism for its formation. J Gen Virol 85, 1853-1857.
48. Kantzanou, M., Lucas, M., Barnes, E., Komatsu, H., Dusheiko, G., Ward, S., Harcourt, G. & Klenerman, P. (2003). Viral escape and T cell exhaustion in hepatitis C virus infection analysed using class I peptide tetramers. Immunol Lett 85, 165-171.
49. Kao, J. H., Chen, P. J., Lai, M. Y. & Chen, D. S. (1993). Superinfection of heterologous hepatitis C virus in a patient with chronic type C hepatitis. Gastroenterology 105, 583-587.
50. Kato, T., Date, T., Miyamoto, M., Furusaka, A., Tokushige, K., Mizokami, M. & Wakita, T. (2003). Efficient replication of the genotype 2a hepatitis C virus subgenomic replicon. Gastroenterology 125, 1808-1817.
51. Kelleher, A. D., Long, C., Holmes, E C. & 15 other authors (2001). Clustered mutations in HIV-1 gag are consistently required for escape from HLA-B27-restricted cytotoxic T lymphocyte responses. J Exp Med 193, 375-386.
52. Kimura, M. (1968). Genetic variability maintained in a finite population due to mutational production of neutral and nearly neutral isoalleles. Genet Res 11, 247-269.
53. Kimura, M. (1983). The Neutral Theory of Molecular Evolution. Cambridge: Cambridge University Press.
54. King, J. L. & Jukes, T. H. (1969). Non-Darwinian evolution. Science 164, 788-798.
55. Kumar, U., Brown, J., Monjardino, J. & Thomas, H. C. (1993). Sequence variation in the large envelope glycoprotein (E2 /NS1) of hepatitis C virus during chronic infection. J Infect Dis 167 726-730.
56. Kuo, G., Choo, Q. L., Alter, H. J. & 17 other authors (1989). An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 244, 362-364.
57. Lai, M. E., Mazzoleni, A. P., Balestriesi, A., Argiolu, F., De Virgilis, S., Cao, A., Purcell, R. H. & Farci, P. (1994). Hepatitis C virus in multiple episodes of acute hepatitis in polytransfused thalassaemic children. Lancet 343, 388-390.
58. Lamarre, D., Anderson, P. C., Bailey, M. & 25 other authors (2003). An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 426, 186-189.
59. Lanford, R. E., Guerra, B., Lee, H., Averett, D. R., Pfeiffer, B., Chavez, D., Notvall, L. & Bigger, C. (2003). Antiviral effect and virus-host interactions in response to alpha interferon, gamma interferon, poly(I)-poly(C), tumor necrosis factor alpha, and ribavirin in hepatitis C virus subgenomic replicons. J Virol 77, 1092-1104.
60. Lechner, F., Wong, D. K. H., Dunbar, P. R. & 7 other authors (2000). Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med 191, 1499-1512.
61. Lee, A. Y., Polakos, N. K., Often, G. R., Ulmer, J. B., Houghton, M. & Paliard, X. (2000). Quantification of the number of cytotoxic T cells specific for an immunodominant HCV-specific CTL epitope primed by DNA immunization. Vaccine 18, 1962-1968.
62. Leslie, A. J., Pfafferott, K. J., Chetty, P. & 26 other authors (2004). HIV evolution: CTL escape mutation and reversion after transmission. Nat Med 10, 282-289.
63. Lohmann, V., Körner, F., Koch, J.-O., Herian, U., Theilmann, L. & Bartenschlager, R. (1999). Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285, 110-113.
64. Lu, L., Pilot-Matias, T. J., Stewart K. D. & 7 other authors (2004). Mutations conferring resistance to a potent hepatitis C virus serine protease inhibitor in vitro. Antimicrob Agents Chemother 48, 2260-2266.
65. Macdonald, A. & Harris, M. (2004). Hepatitis C virus NS5A: tales of a promiscuous protein. J Gen Virol 85, 2485-2502.
66. Majumder, M., Ghosh, A. K, Steele, R., Ray, R. & Ray, R. B. (2001). Hepatitis C virus NS5A physically associates with p53 and regulates p21/waf1 gene expression in a p53-dependent manner. J Virol 75, 1401-1407.
67. Makuwa, M., Souquière, S., Telfer, P. & 7 other authors (2003). Occurrence of hepatitis viruses in wild-born non-human primates: a 3 year (1998-2001) epidemiological survey in Gabon. J Med Primatol 32, 307-314.
68. Mazzeo, C., Azzaroli, F., Giovanelli, S. & 9 other authors (2003). Ten year incidence of HCV infection in northern Italy and frequency of spontaneous viral clearance. Gut 52, 1030-1034.
69. Mellor, J., Holmes, E. C., Jarvis, L. M., Yap, P. L., Simmonds, P. & The International HCV Collaborative Study Group (1995 . Investigation of the pattern of hepatitis C virus sequence diversity in different geographical regions: implications for virus classification. J Gen Virol 76, 2493-2507.
70. Menéndez, C., Sánchez-Tapias, J.-M., Alonso, P.-L. & 8 other authors (1999). Molecular evidence of mother-to-infant transmission of hepatitis G virus among women without known risk factors for parenteral infections. J Clin Microbiol 37, 2333-2336.
71. Mizokami, M., Gojobori, T., Ohba, K., Ikeo, K., Ge, X-M., Ohno, T., Orito, E. & Lau, J. Y. N. (1996). Hepatitis C virus types 7, 8 and 9 should be classified as type 6 subtypes. J Hepatol 24 622-624.
72. Mortimer, P. P. (1995). Arsphenamine jaundice and the recognition of instrument-borne virus infection. Genitourin Med 71, 109-119.
73. Murakami, T., Enomoto, N., Kurosaki, M., Izumi, N., Marumo, F. & Sato, C. (1999). Mutations in nonstructural protein 5A gene and response to interferon in hepatitis C virus genotype 2 infection. Hepatology 30, 1045-1053.
74. Ndjomou, J., Pybus, O. G. & Matz, B. (2003). Phylogenetic analysis of hepatitis C virus isolates indicates a unique pattern of endemic infection in Cameroon. J Gen Virol 84, 2333-2341.
75. Neumann, A. U., Lam, N. P., Dahari, H., Gretch, D. R., Wiley, T. E., Layden, T. J. & Perelson, A. S. (1998). Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-a therapy. Science 282, 103-107.
76. Nousbaum, J.-B., Polyak, S. J., Ray, S. C., Sullivan, D. G., Larson, A. M., Carithers, R. L., Jr & Gretch, D. R. (2000). Prospective characterization of full-length hepatitis C virus NS5A quasispecies during induction and combination antiviral therapy. J Virol 74, 9028-9038.
77. Okamoto, H., Kojima, M., Okada, S. & 7 other authors (1992). Genetic drift of hepatitis C virus during an 8.2-year infection in a chimpanzee: variability and stability. Virology 190, 894-899.
78. Pause, A., Kukolj, G., Bailey, M. & 11 other authors (2003). An NS3 serine protease inhibitor abrogates replication of subgenomic hepatitis C virus RNA. J Biol Chem 278, 20374-20380.
79. Pavesi, A. (2001). Origin and evolution of GBV-C/hepatitis G virus and relationships with ancient human migrations. J Mol Evol 53, 104-113.
80. Pavio, N., Taylor, D. R. & Lai, M. M. C. (2002). Detection of a novel unglycosylated form of hepatitis C virus E2 envelope protein that is located in the cytosol and interacts with PKR. J Virol 76, 1265-1272.
81. Pawlotsky, J.-M. (2003a). Mechanisms of antiviral treatment efficacy and failure in chronic hepatitis C. Antiviral Res 59, 1-11.
82. Pawlotsky, J.-M. (2003b). The nature of interferon-α resistance in hepatitis C virus infection. Curr Opin Infect Dis 16, 587-592.
83. Pestova, T. V., Shatsky, I. N., Fletcher, S. P., Jackson, R. J. & Hellen, C. U. T. (1998). A prokaryotic-like mode of cytoplasmic eukaryotic ribosome binding to the initiation codon during internal translation initiation of hepatitis C and classical swine fever virus RNAs. Genes Dev 12, 67-83.
84. Pietschmann, T., Lohmann, V., Kaul, A., Krieger, N., Rinck, G., Rutter, G., Strand, D. & Bartenschlager, R. (2002). Persistent and transient replication of full-length hepatitis C virus genomes in cell culture. J Virol 76, 4008-4021.
85. Player, M. R. & Torrence, P. F. (1998). The 2-5A system: modulation of viral and cellular processes through acceleration of RNA degradation. Pharmacol Ther 78, 55-113.
86. Polyak, S. J., Khabar, K. S. A., Paschal, D. M., Ezelle, H. J., Duverlie, G., Barber, G. N., Levy, D. E., Mukaida, N. & Gretch, D. R. (2001). Hepatitis C virus nonstructural 5A protein induces interleukin-8, leading to partial inhibition of the interferon-induced antiviral response. J Virol 75, 6095-6106.
87. Power, J. P., Lawlor, E., Davidson, F., Yap, P. L, Kenny-Walsh, E., Whelton, M. J. & Walsh, T. J. (1994). Hepatitis C viraemia in recipients of Irish intravenous anti-D immunoglobulin. Lancet 344, 1166-1167.
88. Pradat, P. & Trepo, C. (2000). HCV: epidemiology, modes of transmission and prevention of spread. Baillières Best Pract Res Clin Gastroenterol 14, 201-210.
89. Pybus, O. G., Charleston, M. A., Gupta, S., Rambaut, A., Holmes, E. C. & Harvey, P. H. (2001). The epidemic behavior of the hepatitis C virus. Science 292, 2323-2325.
90. Pybus, O. G., Drummond, A. J., Nakano, T., Robertson, B. H. & Rambaut, A. (2003). The epidemiology and iatrogenic transmission of hepatitis C virus in Egypt: a Bayesian coalescent approach. Mol Biol Evol 20, 381-387.
91. Quer, J., Murillo, P., Martell, M., Gómez, J., Esteban, J. I., Esteban, R. & Guardia, J. (2004). Subtype mutations in the envelope 2 region including phosphorylation homology domain of hepatitis C virus do not predict effectiveness of antiviral therapy. J Viral Hepat 11, 45-54.
92. Ray, S. C., Arthur, R. R., Carella, A., Bukh, J. & Thomas, D. L. (2000). Genetic epidemiology of hepatitis C virus throughout Egypt. J Infect Dis 182, 698-707.
93. Reiser, M. (2004). Antiviral effect of BILN 2061, a novel HCV serine protease inhibitor, after oral treatment over 2 days in patients with chronic hepatitis C, non-genotype 1. In Program and Abstracts of the 54th Annual Meeting of the American Association for the Study of Liver Diseases, 24-28 October 2003, Boston, MA, USA.
94. Resti, M., Jara, P., Hierro, L., Azzari, C., Giacchino, R., Zuin, G., Zancan, L., Pedditzi, S. & Bortolotti, F. (2003). Clinical features and progression of perinatally acquired hepatitis C virus infection. J Med Virol 70, 373-377.
95. Reyes, G. R. (2002). The nonstructural NS5A protein of hepatitis C virus: an expanding, multifunctional role in enhancing hepatitis C virus pathogenesis. J Biomed Sci 9, 187-197.
96. Rodríguez-López, M., Riezu-Boj, J. I., Ruiz, M., Berasain, C., Civeira, M. P., Prieto, J. & Borrás-Cuesta, F. (1999). Immunogenicity of variable regions of hepatitis C virus proteins: selection and modification of peptide epitopes to assess hepatitis C virus genotypes by ELISA. J Gen Virol 80, 727-738.
97. Rubbia-Brandt, L., Quadri, R., Abid, K. & 8 other authors (2000). Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J Hepatol 33, 106-115.
98. Ruggieri, A., Argentini, C., Kouruma, F., Chionne, P., D'Ugo, E., Spada, E., Dettori, S., Sabbatani, S. & Rapicetta, M. (1996). Heterogeneity of hepatitis C virus genotype 2 variants in West Central Africa (Guinea Conakry). J Gen Virol 77, 2073-2076.
99. Saito, T., Ito, T., Ishiko, H., Yonaha, M., Morikawa, K, Miyokawa, A. & Mitamura, K. (2003). Sequence analysis of PePHD within HCV E2 region and correlation with resistance of interferon therapy in Japanese patients infected with HCV genotypes 2a and 2b. Am J Gastroenterol 98, 1377-1383.
100. Santti, J., Hyypiä, T., Kinnunen, L. & Salminen, M. (1999). Evidence of recombination among enteroviruses. J Virol 73, 8741-8749.
101. Sarisky, R. T. (2004). Non-nucleoside inhibitors of the HCV polymerase. J Antimicrob Chemother 54, 14-16.
102. Sarrazin, C., Herrmann, E., Bruch, K. & Zeuzem, S. (2002). Hepatitis C virus nonstructural 5A protein and interferon resistance: a new model for testing the reliability of mutational analyses. J Virol 76, 11079-11090.
103. Saunders, L. R. & Barber, G. N. (2003). The dsRNA binding protein family: critical roles, diverse cellular functions. FASEB J 17, 961-983.
104. Seeff, L. B. (2002). Natural history of chronic hepatitis C. Hepatology 36, S35-S46.
105. Seeff, L. B., Hollinger, F. B., Alter, H. J. & 21 other authors (2001). Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: a National Heart, Lung, and Blood Institute collaborative study. Hepatology 33, 455-463.
106. Serfaty, L., Andreani, T., Giral, P., Carbonell, N., Chazouilléres, O. & Poupon, R. (2001). Hepatitis C virus induced hypobetalipoproteinemia: a possible mechanism for steatosis in chronic hepatitis C. J Hepatol 34, 428-434.
107. Sheridan, I., Pybus, O. G., Holmes, E. C. & Klenerman, P. (2004). High-resolution phylogenetic analysis of hepatitis C virus adaptation and its relationship to disease progression. J Virol 78, 3447-3454.
108. Simmonds, P. (2001). The origin and evolution of hepatitis viruses in humans. J Gen Virol 82, 693-712.
109. Simmonds, P. & Smith, D. B. (1999). Structural constraints on RNA virus evolution. J Virol 73, 5787-5794.
110. Simmonds, P., Holmes, E. C., Cha, T.-A. & 7 other authors (1993). Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J Gen Virol 74, 2391-2399.
111. Simmonds, P., Tuplin, A. & Evans, D. J. (2004). Detection of genome-scale ordered RNA structure (GORS) in genomes of positive-stranded RNA viruses: implications for virus evolution and host persistence. RNA 10, 1337-1351.
112. Simons, J. N., Pilot-Matias, T. J., Leary, T. P. & 9 other authors (1995). Identification of two flavivirus-like genomes in the GB hepatitis agent. Proc Nad Acad Sci U S A 92, 3401-3405.
113. Smith, D. B., Pathirana, S., Davidson, F., Lawlor, E., Power, J., Yap, P. L & Simmonds, P. (1997). The origin of hepatitis C virus genotypes. J Gen Virol 78, 321-328.
114. Stuyver, L., Rossau, R., Wyseur, A., Duhamel, M., Vanderborght, B., Van Heuverswyn, H. & Maertens, G. (1993). Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay. J Gen Virol 74, 1093-1102.
115. Takaki, A., Wiese, M., Maertens, G., Depla, E., Seifeit, U., Liebetrau, A., Miller, J. L., Manns, M. P. & Rehermann, B. (2000 . Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat Med 6, 578-582.
116. Tan, S.-L. & Katze, M. G. (2001). How hepatitis C virus counteracts the interferon response: the jury is still out on NS5A. Virology 284, 1-12.
117. Tan, S.-L., Nakao, H., He, Y., Vijaysri, S., Neddermann, P., Jacobs, B. L., Mayer, B. J. & Katze, M. G. (1999). NS5A, a nonstructural protein of hepatitis C virus, binds growth factor receptor-bound protein 2 adaptor protein in a Src homology 3 domain/ligand-dependent manner and perturbs mitogenic signaling. Proc Natl Acad Sci U S A 96, 533-5538.
118. Taniguchi, S., Okamoto, H., Sakamoto, M. & 7 other authors (1993). A structurally flexible and antigenically variable N-terminal domain of the hepatitis C virus E2/NS1 protein: implication for an escape from antibody. Virology 195, 297-301.
119. Taylor, D. R., Shi, S. T., Romano, P. R., Barber, G. N. & Lai, M. M. C. (1999). Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. Science 285, 107-110.
120. Thibeault, D., Bousquet, C., Gingras, R., Lagacé, L., Maurice, R., White, P. W. & Lamarre, D. (2004). Sensitivity of NS3 serine proteases from hepatitis C virus genotypes 2 and 3 to the inhibitor BILN 2061. J Virol 78, 7352-7359.
121. Thimme, R., Oldach, D., Chang, K M., Steiger, C., Ray, S. C. & Chisari, F. V. (2001). Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med 194, 1395-1406.
122. Thomas, D. L. (2000). Hepatitis C epidemiology. Curr Top Microbiol Immunol 242, 25-41.
123. Tokita, H., Okamoto, H., Tsuda, F. & 7 other authors (1994a). Hepatitis C virus variants from Vietnam are classifiable into the seventh, eighth, and ninth major genetic groups. Proc Natl Acad Sci U S A 91, 11022-11026.
124. Tokita, H., Shrestha, S. M., Okamoto, H., Sakamoto, M., Hirokita, M., Iizuka, H., Shrestha, S., Miyakawa, Y. & Mayumi, M. (1994b). Hepatitis C virus variants from Nepal with novel genotypes and their classification into the third major group. J Gen Virol 75, 931-936.
125. Tokita, H., Okamoto, H., Luengrojanakul, P., Vareesangthip, K, Chainuvati, T., Iizuka, H., Tsuda, F., Miyakawa, Y. & Mayumi, M. (1995). Hepatitis C virus variants from Thailand classifiable into five novel genotypes in the sixth (6b), seventh (7c, 7d) and ninth (9b, 9c) major genetic groups. J Gen Virol 76, 2329-2335.
126. Trozzi, C., Bartholomew, L., Ceccacci, A. & 10 other authors (2003). In vitro selection and characterization of hepatitis C virus serine protease variants resistant to an active-site peptide inhibitor. J Virol 77, 3669-3679.
127. Tuplin, A., Wood, J., Evans, D. J., Patel, A. H. & Simmonds, P. (2002). Thermodynamic and phylogenetic prediction of RNA secondary structures in the coding region of hepatitis C virus. RNA 8, 824-841.
128. Tuplin, A., Evans, D. J. & Simmonds, P. (2004). Detailed mapping of RNA secondary structures in core and NS5B-encoding region sequences of hepatitis C virus by RNase cleavage and novel bioinformatic prediction methods. J Gen Virol 85, 3037-3047.
129. Varaklioti, A., Vassilaki, N., Georgopoulou, U. & Mavromara, P. (2002). Alternate translation occurs within the core coding region of the hepatitis C viral genome. J Biol Chem 277 17713-17721.
130. Walewski, J. L., Keller, T. R., Stump, D. D. & Branch, A. D. (2001). Evidence for a new hepatitis C virus antigen encoded in an overlapping reading frame. RNA 7, 710-721.
131. Wang, C., Pflugheber, J., Sumpter, R., Jr, Sodora, D. L., Hui, D., Sen, G. C. & Gale, M., Jr (2003). Alpha interferon induces distinct translational control programs to suppress hepatitis C virus RNA replication. J Virol 77, 3898-3912.
132. Wansbrough-Jones, M. H., Frimpong, E., Cant, B., Harris, K., Evans, M. R. W. & Teo, C. G. (1998). Prevalence and genotype of hepatitis C virus infection in pregnant women and blood donors in Ghana. Trans R Soc Trop Med Hyg 92, 496-499.
133. Wasley, A. & Alter, M. J. (2000). Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis 20, 1-16.
134. Watanabe, H., Nagayama, K., Enomoto, N., Itakura, J., Tanabe, Y., Hamano, K., Izumi, N., Sato, C. & Watanabe, M. (2003a . Sequence elements correlating with circulating viral load in genotype 1b hepatitis C virus infection. Virology 311, 376-383.
135. Watanabe, H., Nagayama, K., Enomoto, N., Itakura, J., Tanabe, Y., Sato, C., Izumi, N. & Watanabe, M. (2003b). Amino acid substitutions in PKR-eIF2 phosphorylation homology domain (PePHD) of hepatitis C virus E2 protein in genotype 2a/2b and 1b in Japan and interferon efficacy. Hepatol Res 26, 268-274.
136. Waterhouse, P. M., Wang, M.-B. & Lough, T. (2001). Gene silencing as an adaptive defence against viruses. Nature 411, 834-842.
137. Weiner, A. J., Geysen, H. M., Christopherson, C. & 12 other authors (1992). Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: potential role in chronic HCV infections. Proc Natl Acad Sci U S A 89, 3468-3472.
138. Witherell, G. W. & Beineke, P. (2001). Statistical analysis of combined substitutions in nonstructural 5A region of hepatitis C virus and interferon response. J Med Virol 63, 8-16.
139. Xu, L.-Z., Larzul, D., Delaporte, E., Bréchot, C. & Kremsdorf, D. (1994). Hepatitis C virus genotype 4 is highly prevalent in central Africa (Gabon). J Gen Virol 75, 2393-2398.
140. Xu, Z., Choi, J., Yen, T. S. B., Lu, W., Strohecker, A., Govindarajan, S., Chien, D., Selby, M. J. & Ou, J. (2001). Synthesis of a novel hepatitis C virus protein by ribosomal frameshift. EMBO J 20, 3840-3848.
141. Yee, T. T., Griffioen, A., Sabin, C. A., Dusheiko, G. & Lee, C. A. (2000). The natural history of HCV in a cohort of haemophilic patients infected between 1961 and 1985. Gut 47, 845-851.
142. You, S., Stump, D. D., Branch, A. D. & Rice, C. M. (2004). A cis-acting replication element in the sequence encoding the NS5B RNA-dependent RNA polymerase is required for hepatitis C virus RNA replication. J Virol 78, 1352-1366.
143. Zeuzem, S. (2004). Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well? Ann Intern Med 140, 370-381.
144. Zhang, Z.-X, Chen, M., Sönnerborg, A. & Sällberg, M. (1994). Antigenic structure of the complete nonstructural (NS) 2 and 5 proteins of hepatitis C virus (HCV): anti-HCV NS2 and NS5 antibody reactivities in relation to HCV serotype, presence of HCV RNA, and acute HCV infection. Clin Diagn Lab Immunol 1, 290-294.